BioCryst Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
BioCryst Pharmaceuticals, Inc.‘s stocks are currently a part of 220 hedge funds’ portfolios, which represents 70.82% of the total amount of its stocks outstanding. This makes up a total of 126.85M shares of BioCryst Pharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 7.62% or 8.98M shares more. As for the holding position changes, 28.64% (63) of current hedge fund investors increased the number of shares held, 30.91% (68) of current holders sold a part of the shares held, and 9.55% (21) closed the holdings completely. 47 hedge funds are new holders of BioCryst Pharmaceuticals, Inc. stock in Q1 2022, it is 21.36% of total holders.
Hedge funds holding BioCryst Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 113 |
|---|---|
| Q3 2017 | 119 |
| Q4 2017 | 113 |
| Q1 2018 | 98 |
| Q2 2018 | 102 |
| Q3 2018 | 113 |
| Q4 2018 | 121 |
| Q1 2019 | 130 |
| Q2 2019 | 114 |
| Q3 2019 | 112 |
| Q4 2019 | 133 |
| Q1 2020 | 132 |
| Q2 2020 | 160 |
| Q3 2020 | 149 |
| Q4 2020 | 171 |
| Q1 2021 | 185 |
| Q2 2021 | 189 |
| Q3 2021 | 191 |
| Q4 2021 | 199 |
| Q1 2022 | 220 |
Hedge funds changes in BioCryst Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 15 | 45 | 27 | 16 | 10 |
|---|---|---|---|---|---|
| Q3 2017 | 23 | 41 | 28 | 17 | 10 |
| Q4 2017 | 20 | 44 | 22 | 25 | 2 |
| Q1 2018 | 9 | 34 | 32 | 23 | 0 |
| Q2 2018 | 13 | 23 | 36 | 9 | 21 |
| Q3 2018 | 23 | 37 | 26 | 12 | 15 |
| Q4 2018 | 22 | 30 | 41 | 15 | 13 |
| Q1 2019 | 21 | 52 | 25 | 12 | 20 |
| Q2 2019 | 18 | 44 | 29 | 30 | -7 |
| Q3 2019 | 16 | 37 | 35 | 19 | 5 |
| Q4 2019 | 39 | 55 | 24 | 18 | -3 |
| Q1 2020 | 25 | 52 | 37 | 24 | -6 |
| Q2 2020 | 47 | 56 | 37 | 20 | 0 |
| Q3 2020 | 25 | 59 | 43 | 35 | -13 |
| Q4 2020 | 37 | 55 | 56 | 16 | 7 |
| Q1 2021 | 46 | 54 | 69 | 31 | -15 |
| Q2 2021 | 42 | 58 | 59 | 36 | -6 |
| Q3 2021 | 30 | 64 | 66 | 26 | 5 |
| Q4 2021 | 34 | 75 | 52 | 28 | 10 |
| Q1 2022 | 47 | 63 | 68 | 21 | 21 |
Hedge funds changes in BioCryst Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 6,266,000 | 2,011,000 |
|---|---|---|
| Q3 2017 | 1,105,000 | 4,833,000 |
| Q4 2017 | 907,000 | 577,000 |
| Q1 2018 | 895,000 | 438,000 |
| Q2 2018 | 972,000 | 484,000 |
| Q3 2018 | 1,861,000 | 1,457,000 |
| Q4 2018 | 2,101,000 | 1,444,000 |
| Q1 2019 | 8,868,000 | 5,794,000 |
| Q2 2019 | 4,457,000 | 4,863,000 |
| Q3 2019 | 1,023,000 | 185,000 |
| Q4 2019 | 1,840,000 | 570,000 |
| Q1 2020 | 3,054,000 | 396,000 |
| Q2 2020 | 11,195,000 | 3,314,000 |
| Q3 2020 | 4,403,000 | 4,640,000 |
| Q4 2020 | 10,462,000 | 12,447,000 |
| Q1 2021 | 37,160,000 | 23,248,000 |
| Q2 2021 | 81,804,000 | 68,502,000 |
| Q3 2021 | 90,590,000 | 53,100,000 |
| Q4 2021 | 77,855,920 | 38,679,995 |
| Q1 2022 | 92,131,000 | 34,827,000 |